Helena M. Earl, MBBS, PhD: Is a Shorter Duration of Trastuzumab Effective in Early-Stage HER2-Positive Breast Cancer?

Posted: Tuesday, October 19, 2021

Helena M. Earl, MBBS, PhD, of the University of Cambridge, offers key insights into the rationale for a study she conducted on whether a duration of less than the standard of 12 months of adjuvant trastuzumab is noninferior for treatment outcomes in patients with HER2-positive early breast cancer. She also describes how clinicians should interpret the findings.